To further strengthen the anti-tumor activity, STO-1 treatment evokes intra-tumor recruitment of activated and tumoricidal NK cells and CD8+ cytotoxic T-cells (Figure 6) [4,5,6,46,64]. The gene discussed is CD8A; the disease is neoplasm.